Cash Flow Management for EU Independent Veterinary Practices

Drug and Consumable Inventory Management#

Drug stock represents 25–40% of EU veterinary practice revenue and is the largest working capital item. Overstocking drugs with short expiry dates or slow turnover creates write-off costs; understocking disrupts clinical workflows and damages client experience. Implement par levels for high-usage drugs based on rolling 12-week dispensing data; review and adjust quarterly. Negotiate monthly account terms with veterinary wholesalers (MWI, NVS, Henry Schein) rather than paying on delivery — even 30-day terms meaningfully improve cash flow at high drug spend volumes. Participate in group purchasing through your professional association where available to access volume pricing without commensurate stock commitment.

Client Payment Policy and Credit Risk#

EU veterinary practices that offer open credit to clients — invoicing after treatment with payment due in 30 days — carry unnecessary credit risk and administrative burden. Requiring payment at point of consultation is standard practice in most EU markets and does not damage the client relationship if communicated clearly. Where treatments involve significant cost for clients, partner with veterinary finance providers (Medivet Finance, Vetpay) who offer 0% or low-interest payment plans to clients — this improves client ability to pay without the practice carrying the credit risk. Track debtor days monthly; above 15 days for a cash-at-consultation practice signals collection procedure failures.

Health Plan Subscriptions and Recurring Revenue#

EU veterinary practice health plan subscriptions — monthly direct debit plans covering annual vaccinations, health checks, flea and worm treatment, and discounts on additional services — transform cash flow from episodic to monthly recurring. Practices with 30%+ of their registered patients on health plans receive predictable monthly direct debit income that funds drug purchasing and staff costs regardless of consultation volume fluctuations. Plans priced at €20–€45 per month per pet generate €240–€540 annually per enrolled pet with significantly lower acquisition cost than individual consultation marketing. Build plan enrolment through every annual vaccination and health check appointment — offer the plan at point of highest client engagement.

Equipment Investment and Financing#

EU veterinary practice equipment — digital X-ray, ultrasound, in-house laboratory analysers, dental units — requires periodic investment of €20K–€200K per major equipment category. Funding this from operating cash flow disrupts practice liquidity; veterinary-specific finance (HP, lease, or borrow through specialist veterinary lenders) is more appropriate. Evaluate equipment investments on: the additional revenue they enable (in-house lab reduces lab send-away cost and generates in-house margin); the clinical quality improvement; and the competitive positioning impact. In-house capability that corporate consolidator practices offer is increasingly important for retaining clients who have access to better-resourced corporate alternatives nearby.

Competing with Corporate Consolidators#

EU veterinary consolidation (IVC Evidensia, CVS Group, Medivet) has accelerated, giving corporate practices purchasing power, management support, and brand advantages that independent practices struggle to match on cost alone. Independent EU practices compete on: deeper client relationships with practice owners who are clinically involved; community roots and local reputation; faster decision-making on clinical investments; and specialist clinical interest areas that smaller corporate branches cannot replicate. Price competitively but do not match corporate discounting — it erodes margin without matching the corporate cost structure. Instead, invest in client experience, outcome communication, and clinical reputation that justifies maintaining premium positioning.